Cargando…

Immune marker expression of irradiated mesothelioma cell lines

BACKGROUND: Though immune checkpoint inhibition has recently shown encouraging clinical efficacy in mesothelioma, most patients do not respond. Combining immune checkpoint inhibition with radiotherapy presents an attractive option for improving treatment responses owing to the various immunomodulato...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chang, Faith, Keam, Synat, Hoang, Tracy Seymour, Creaney, Jenette, Gill, Suki, Nowak, Anna K., Ebert, Martin, Cook, Alistair M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9659742/ https://www.ncbi.nlm.nih.gov/pubmed/36387076 http://dx.doi.org/10.3389/fonc.2022.1020493

Ejemplares similares

Effects of Photon Radiation on DNA Damage, Cell Proliferation, Cell Survival, and Apoptosis of Murine and Human Mesothelioma Cell Lines
por: Keam, Synat, et al.
Publicado: (2022)

Enhancing the efficacy of immunotherapy using radiotherapy
por: Keam, Synat, et al.
Publicado: (2020)

Antiangiogeneic Strategies in Mesothelioma
por: Nowak, Anna K., et al.
Publicado: (2020)

Discovery of new biomarkers for malignant mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2015)

Clinical evidence for synergy between immunotherapy and radiotherapy (SITAR)
por: Gill, Suki, et al.
Publicado: (2022)

Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2014)

How Our Continuing Studies of the Pre-clinical Inbred Mouse Models of Mesothelioma Have Influenced the Development of New Therapies
por: Robinson, Bruce W.S., et al.
Publicado: (2022)

Hyaluronic acid in viscous malignant mesothelioma pleural effusion
por: Cheah, Hui Min, et al.
Publicado: (2020)

Auto-Antibodies to β-F1-ATPase and Vimentin in Malignant Mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2011)

Tumour associated lymphocytes in the pleural effusions of patients with mesothelioma express high levels of inhibitory receptors
por: Chee, Jonathan, et al.
Publicado: (2018)

Pleural Fluid Mesothelin as an Adjunct to the Diagnosis of Pleural Malignant Mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2014)

Secreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo
por: Greening, David W., et al.
Publicado: (2016)

Randomised placebo-controlled cross-over study examining the role of anamorelin in mesothelioma (The ANTHEM study): rationale and protocol
por: Hoon, Siao Nge, et al.
Publicado: (2020)

Risk of cardiac implantable device malfunction in cancer patients receiving proton therapy: an overview
por: Mirzaei, Milad, et al.
Publicado: (2023)

Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma—a phase 3 randomised trial
por: Kok, Peey Sei, et al.
Publicado: (2022)

The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy
por: Chu, Gerard J., et al.
Publicado: (2019)

Immune Microenvironment and Genetics in Malignant Pleural Mesothelioma
por: Wadowski, Benjamin, et al.
Publicado: (2021)

Tumor Immune Microenvironment and Genetic Alterations in Mesothelioma
por: Hiltbrunner, Stefanie, et al.
Publicado: (2021)

Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma
por: Meniawy, T M, et al.
Publicado: (2013)

Consistent gene expression profiles in MexTAg transgenic mouse and wild type mouse asbestos-induced mesothelioma
por: Robinson, Cleo, et al.
Publicado: (2015)

Calretinin as a blood-based biomarker for mesothelioma
por: Johnen, Georg, et al.
Publicado: (2017)

Mitochondria-derived reactive oxygen species drive GANT61-induced mesothelioma cell apoptosis
por: Lim, Chuan Bian, et al.
Publicado: (2015)

ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4–10 years in advance of clinical symptoms
por: Morré, D. James, et al.
Publicado: (2016)

Comparison of the Diagnostic Accuracy of the MSLN Gene Products, Mesothelin and Megakaryocyte Potentiating Factor, as Biomarkers for Mesothelioma in Pleural Effusions and Serum
por: Creaney, Jenette, et al.
Publicado: (2013)

Erratum to: ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4–10 years in advance of clinical symptoms
por: Morré, D. James, et al.
Publicado: (2016)

Aurora Kinase A as a Diagnostic and Prognostic Marker of Malignant Mesothelioma
por: Guo, Zhenying, et al.
Publicado: (2021)

Response to comment on ‘Existing prognostic models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma'
por: Meniawy, T M, et al.
Publicado: (2014)

MicroRNA Signatures in Malignant Pleural Mesothelioma Effusions
por: Birnie, Kimberly A., et al.
Publicado: (2019)

Prognostic Role of Tumor Immune Microenvironment in Pleural Epithelioid Mesothelioma
por: Ollila, Hely, et al.
Publicado: (2022)

Targeting Aggressive Cancer Stem Cells in Glioblastoma
por: Seymour, Tracy, et al.
Publicado: (2015)

Whole exome sequencing of an asbestos-induced wild-type murine model of malignant mesothelioma
por: Sneddon, Sophie, et al.
Publicado: (2017)

Current State of Pleural-Directed Adjuncts Against Malignant Pleural Mesothelioma
por: Choi, Agnes Y., et al.
Publicado: (2022)

Tumor Microenvironment-Associated Immune-Related Genes for the Prognosis of Malignant Pleural Mesothelioma
por: Xu, Xiaoling, et al.
Publicado: (2020)

Protocol for PIT: a phase III trial of prophylactic irradiation of tracts in patients with malignant pleural mesothelioma following invasive chest wall intervention
por: Bayman, N, et al.
Publicado: (2016)

Guidelines for cytopathologic diagnosis of epithelioid and mixed type malignant mesothelioma. Complementary statement from the International Mesothelioma Interest Group, also endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology
por: Hjerpe, Anders, et al.
Publicado: (2015)

Identification of a CD8+ T-cell response to a predicted neoantigen in malignant mesothelioma
por: Sneddon, Sophie, et al.
Publicado: (2019)

Oncolytic Viral Therapy for Mesothelioma
por: Pease, Daniel F., et al.
Publicado: (2017)

Preclinical Models of Malignant Mesothelioma
por: Testa, Joseph R., et al.
Publicado: (2020)

Immunotherapy in Malignant Pleural Mesothelioma
por: de Gooijer, Cornedine J., et al.
Publicado: (2020)

Editorial: Epigenetic Modifications in Mesothelioma
por: Cheng, Yuen Yee, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_52og51bgn05qlf9hfm77vff9s4